Navigation Links
CCNY professor gets grant to develop 'artificial blood'
Date:12/7/2010

As a post-doc at The University of Pennsylvania, Dr. Ron Koder, assistant professor of physics at The City College of New York, was part of a team that devised a novel method for producing an artificial protein capable of transporting oxygen, similar to human neuroglobin. He was recently awarded a three-year $1.3 million grant from the U.S. Department of Defense to develop an artificial blood that can be administered to injured troops on the battlefield.

"Engineered blood substitutes have a lot of attractive properties compared to blood drawn from people," he said. "No typing is required, you don't have to worry about refrigeration or freshness and there is no risk of infection." They can save lives, as well, since severely wounded servicemen and women sometimes die before they can be transported to a hospital and given a transfusion.

Professor Koder will use the grant to conduct laboratory studies to improve the stability and other properties of the protein. Then, he plans to cross-link the protein into large aggregates to create particles the same size as red blood cells.

Because the artificial hemoglobin binds oxygen in the presences of carbon monoxide, the substance also has the potential to prevent or treat carbon monoxide poisoning, he noted. However, this will not be part of the investigation.

Research like Professor Koder's investigation is part of the emerging field of biological design, a system for producing biological materials from scratch. Other potential applications include fighting AIDS and alternative energy. Biological design was the topic of a daylong symposium Friday, December 3, at the New York Academy of Sciences that Professor Koder helped organize.

"Natural materials are fussy. It's hard to get them to interact," he explained. "The (manmade) stuff is better for engineering more complex systems." Some of the biological design projects underway include developing metabolic pathways that could produce low-cost AIDS drugs, using solar energy to produce bio-fuels through artificial photosynthesis and making methanol from carbon dioxide.


'/>"/>

Contact: Ellis Simon
esimon@ccny.cuny.edu
212-650-6460
City College of New York
Source:Eurekalert

Related biology news :

1. Rensselaer Polytechnic Institute professor Georges Belfort wins biochemical engineering award
2. UTHealth School of Biomedical Informatics professor to be inducted to AIMBE College of Fellows
3. ASU professor named top in state of Arizona
4. UH engineering professors featured in consecutive issues of Science
5. Falling in love more scientific than you think, according to Syracuse University professor
6. NJIT professor helps make case in Science for better biodiversity
7. 1 step closer to a drug treatment for cystic fibrosis, MU professor says
8. USDA awards grant to GSU professor to study childhood obesity dynamics
9. UD Professor Emeritus wins Nobel Prize in Chemistry
10. Louisiana Tech professor partners with local schools to study menu nutrition
11. Nobel Prize for Professor Robert G. Edwards, Editor Emeritus of Reproductive BioMedicine Online
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis zum Jahr 2018 ... mehr als 50 Vertretern aus verschiedenen Branchen wurde aber klar, ... Prognose zu realisieren. ... Zu den Schwierigkeiten für Biobanking-Profis ... die Biobank, die Implementierung Zeit sparender Technologien, ein besseres ...
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... 27, 2017 Four US Biotech ... today, and they are: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), ... Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals Inc. (NASDAQ: ... Trends, market observers are growing more bullish on the ... reforms to free cash held overseas for tax reason ...
(Date:2/27/2017)... , ... February 27, 2017 , ... The Catalyst ... a few in the Midwest offering premix services and private label organic services. , ... laying hens, according Jos Zamzow, chief operating officer of Dynamite Marketing, which owns the ...
(Date:2/24/2017)... ... ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced ... for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ). The ... therapeutic levels of olanzapine for a period of 3 months., “We are honored and ...
(Date:2/24/2017)... SAN FRANCISCO , Feb. 24, 2017 ... that is developing a new category of therapeutics, announced ... trial of SB-030 in peripheral artery disease. The trial ... locally administered single-use therapeutic, in the reduction of restenosis ... reached this critical development milestone for SB-030," said ...
Breaking Biology Technology: